{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-009247","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.652768+00:00","generated_at":"2026-06-01T04:09:56.193340+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Xilio Therapeutics stockholders elect Clancy and Rossi as Class III directors at annual meeting","bullets":["Stockholders elected Paul J. Clancy and Christina Rossi as Class III directors each with ~94.4% of votes cast (excluding broker non-votes).","Auditor Ernst & Young ratified with 26,199,617 votes for (99.6% of votes cast).","Broker non-votes of 6,783,293 on director election; none on auditor ratification."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-009247","json":"https://secwatch.observer/filing/0001558370-24-009247.json","markdown":"https://secwatch.observer/filing/0001558370-24-009247.md","text":"https://secwatch.observer/filing/0001558370-24-009247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024009247/0001558370-24-009247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024009247/xlo-20240613x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:09:56.193340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}